We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

Should you buy Carnival & Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

The Milky Way at night, over Porthgwarra beach in Cornwall
Investing Articles

Is the SpaceX IPO the best growth stock opportunity in a generation?

How about a mix of space exploration, satellite communications, and artificial intelligence? That's what SpaceX stock is all about.

Read more »

Red lorry on M1 motorway in motion near London
Investing Articles

No longer just a grocer: here’s how a shift in strategy could help Tesco shares hit new highs

Mark Hartley looks into the strategic data-driven transition that's helping Tesco become more than just a grocer, and could send…

Read more »

Middle-aged black male working at home desk
Investing Articles

British American Tobacco’s share price slumps 4%! How’s that happened?

British American Tobacco's share price has sunk today, making it the FTSE 100's worst performer. Is it time for dip…

Read more »

A hiker and their dog walking towards the mountain summit of High Spy from Maiden Moor at sunrise
Investing Articles

7.5% yields! Here are 2 very different dividend stocks to consider buying in June

Dividend stocks can be great investments, but they’re not all the same. Stephen Wright outlines two for passive income investors…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Takeover talk! But how much is a £10,000 investment in easyJet shares 5 years ago worth today?

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

Up 41% in 12 months are Barclays shares still worth buying?

Andrew Mackie explores Barclays shares and argues the market may still be valuing the bank using an outdated playbook, despite…

Read more »

Little girl helping her Grandad plant tomatoes in a greenhouse in his garden.
Investing Articles

Why are ITM Power shares 69% off?

ITM Power shares are among the hottest UK stocks of 2026. So how come the share price is still down…

Read more »

Close-up of British bank notes
Investing Articles

As British American Tobacco shares dip, is this a hot buying opportunity?

Are British American Tobacco shares on their way to completing another decade of dividend growth? Let's check out this latest…

Read more »